TVTX

Travere Therapeutics Stock Analysis

AI Rating

Good
  • Quality4/10
  • Growth↑ 8/10
  • Momentum↑ 7/10
Travere Therapeutics sales and earnings growth
TVTX Growth
Good
  • Revenue Y/Y↑ 110.45%
  • EPS Y/Y↑ 92.89%
  • FCF Y/Y↑ 92.56%
Travere Therapeutics gross and profit margin trends
TVTX Profitability
Neutral
  • Gross margin ↑ 97.90%
  • EPS margin↓ -5.20%
  • ROIC↓ -2.40%
Travere Therapeutics net debt vs free cash flow
TVTX Risk
Fair
  • Debt / Equity↑ 2.9
  • Debt / FCF↑ 11.6
  • Interest coverage↓ -1.3

Travere Therapeutics stock volatility is in-line with the overall market. We give it a Fair risk rating.

More Biotechnology stocks ↗